TAK-653 (Osavampator) 2mg – 60 tablets

TAK-653 (Osavampator) 2 mg – 60 research tablets research-grade small-molecule compound in tablet form supplied in a sealed bottle. Studied as a selective positive allosteric modulator (PAM) of AMPA receptors in central nervous system research models.

Research Overview

TAK-653, also known as Osavampator, is a small-molecule research compound developed as a highly selective positive allosteric modulator (PAM) of the AMPA subtype of ionotropic glutamate receptors. In experimental models, TAK-653 enhances glutamatergic signaling by potentiating AMPA receptor responses without directly acting as a full agonist, and is studied in preclinical and clinical research exploring synaptic plasticity, mood regulation and central nervous system function.

Primary Research Areas

• AMPA receptor modulation: Investigated as a selective AMPA receptor PAM, supporting studies on glutamatergic transmission, receptor desensitization and mechanisms that may underlie rapid changes in synaptic efficacy in CNS models.
• Mood and depression research: Evaluated in experimental models and clinical research programs focused on major depressive disorder and mood regulation, where AMPA receptor potentiation is studied as a glutamate-based strategy distinct from classic monoaminergic approaches.
• Cognitive function and memory: Used in laboratory studies investigating learning, working memory and long-term potentiation, where modulation of AMPA receptors is examined in the context of synaptic plasticity and information processing in cortical and hippocampal circuits.
• Synaptic plasticity and network dynamics: Included in research on activity-dependent remodeling of excitatory synapses, changes in excitatory–inhibitory balance and network-level responses to AMPA receptor potentiation across different CNS regions.
• Neuroprotection and functional recovery: Explored in preclinical models assessing how controlled enhancement of AMPA receptor activity may influence neuronal resilience, recovery after functional impairment and downstream pathways linked to neurotrophic signaling.